



Legacy Healthcare to Present RAAINBOW Phase 2/3 Clinical Trail Data at Annual Congress of the Journée Dermatologiques de Paris

Epalinges, Switzerland, 1 December 2023 - - Legacy Healthcare, a Swiss-based biotechnology company developing first-in-class botanical drugs for human health, today announced that it will present phase 2/3 data from its RAAINBOW trial at the 50th annual congress of the Journées Dermatologiques de Paris (JDP) in Paris, France, from 5-9 December 2023.

“Alopecia areata remains a vastly unserved market, particularly for pediatric patients for which there is significant room for innovation,” commented Saad Harti, Chairman & CEO of Legacy Healthcare. “Data from our RAAINBOW study with CINAINU, our first botanical drug, show significant promise and we are dedicated to advancing this and submitting for approval from regulatory authorities around the world to advance patient care.”

Data from the RAAINBOW study was presented by Professor Ulrike Blume Peytavi, MD, Deputy head of Department of Dermatology, Venerology and Allergology at Charité University, Berlin. The Journées Dermatologiques de Paris (JDP) is an esteemed annual congress organized by the Société Française de Dermatologie (SFD), this event serves as a pivotal gathering for dermatology professionals, offering a platform for scientific exchange, innovation, and education. The 2023 JDP hosted over 150 sessions, 850 speakers, and 6,900 participants, marking a 16% increase in attendance. It covered diverse topics like carcinomas, melanomas, and lymphomas while emphasizing ecological and social responsibility initiatives. The congress also enhanced accessibility through a mobile platform for session access and replays.

For more information on the conference, please visit: <https://www.lesjdp.fr/>

About Phase 2/3 RAAINBOW trial

This randomized, placebo-controlled, double-blind study investigated Coacillium in patients from 2 to 18 years of age with alopecia areata. Patients included had moderate alopecia areata (SALT 25-50) and severe alopecia areata (SALT 50-95), and were experiencing a current episode of alopecia areata that had lasted between six months and three years (n=62). Patients were randomized to receive topical Coacillium or placebo (2:1). A treatment period of 6 months was followed by a treatment-free period of 6 months, to evaluate possible disease recurrence in successfully treated patients. The primary endpoint was the relative change in scalp alopecia areata severity score (SALT) from baseline value to be assessed after 24 weeks of treatment, evaluated through global standardised scalp photographs. A key secondary endpoint was the proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. SALT is the standard tool for measurement of the amount of scalp hair loss in alopecia areata.

For more information about the RAAINBOW trial please visit: <https://clinicaltrials.gov/ct2/show/NCT03240627>



About Legacy Healthcare

Legacy Healthcare is a Swiss-based biopharmaceutical company focused on leveraging the pleiotropic activity and strong safety profile of plants to develop prescription botanical drugs that address serious medical conditions. The company's first product candidate, CINAINU, has demonstrated strong safety and efficacy in a phase 2/3 study involving patients suffering from alopecia areata, a chronic autoimmune condition with highly damaging psycho-social issues that impact all who suffer from it, especially children.

For more information about Legacy Healthcare please visit www.legacyhealthcare.ch

Inquiries: contact@leagacyhealthcare.ch;